The Korean Journal of Medicine

  • 제84권2호
  • /
  • Pages.145-157
  • /
  • 2013
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

고형장기이식 환자에서 흔히 보는 감염

Common Infections in Solid Organ Transplant Recipients

  • 이상오 (울산대학교 의과대학 내과학교실)
  • Lee, Sang-Oh (Department of Internal Medicine, University of Ulsan College of Medicine)
  • 발행 : 2013.02.01
⟨ 이전 논문 다음 논문 ⟩

초록

Improved immunosuppressive therapies for solid organ transplantation (SOT) have reduced the incidence of allograft rejection while increasing susceptibility to opportunistic infections. Diagnosis and treatment for infectious disease after SOT are evolving with various preventive strategies, improved microbiologic diagnostic tools, and newer therapeutic regimens. Despite these improvements, various opportunistic infections can develop in SOT recipients. Early and specific diagnosis of infections is essential to guide treatment and minimize nonessential antibiotics. Invasive diagnostic procedures are often required for accurate and timely diagnosis. Here, I reviewed general aspects of common infections in SOT recipients.

키워드

참고문헌

  1. Kasiske BL, Skeans MA, Leighton TR, Ghimire V, Leppke SN, Israni AK. OPTN/SRTR 2011 annual data report: international data. Am J Transplant 2013;13(Suppl 1):S199-S225. https://doi.org/10.1111/ajt.12026
  2. Fishman JA; AST Infectious Diseases Community of Practice. Introduction: infection in solid organ transplant recipients. Am J Transplant 2009;9(Suppl 4):S3-S6. https://doi.org/10.1111/j.1600-6143.2009.02887.x
  3. Lee SO, Kang SH, Abdel-Massih RC, Brown RA, Razonable RR. Spectrum of early-onset and late-onset bacteremias after liver transplantation: implications for management. Liver Transpl 2011;17:733-741. https://doi.org/10.1002/lt.22296
  4. Moon CS, Kim SH, Ki HK, et al. Urinary tract infections in renal transplant recipients. Infect Chemother 2006;38: 123-130.
  5. Abbott KC, Swanson SJ, Richter ER, et al. Late urinary tract infection after renal transplantation in the United States. Am J Kidney Dis 2004;44:353-362. https://doi.org/10.1053/j.ajkd.2004.04.040
  6. Kim YJ, Kim SI, Wie SH, et al. Infectious complications in living-donor liver transplant recipients: a 9-year singlecenter experience. Transpl Infect Dis 2008;10:316-324. https://doi.org/10.1111/j.1399-3062.2008.00315.x
  7. Lee SO, Razonable RR. Current concepts on cytomegalovirus infection after liver transplantation. World J Hepatol 2010;2:325-336. https://doi.org/10.4254/wjh.v2.i9.325
  8. Lee HJ, Chang SH. Prevalence of antibody to cytomegalovirus by anticomplement immunofluorescence test in Korean children. Korean J Infect Dis 1993;25:357-361.
  9. Yang CW, Kim YO, Kim YS, et al. Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients: longitudinal follow-up of CMV pp65 antigenemia assay. Am J Nephrol 1998;18:373-378. https://doi.org/10.1159/000013379
  10. Humar A, Michaels M; AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006;6:262-274. https://doi.org/10.1111/j.1600-6143.2005.01207.x
  11. Fica A, Cervera C, Perez N, et al. Immunohistochemically proven cytomegalovirus end-organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic tests. Transpl Infect Dis 2007;9: 203-210. https://doi.org/10.1111/j.1399-3062.2007.00220.x
  12. Park SY, Kim YH, Han DJ, et al. Efficacy of a strategy for discontinuing preemptive ganciclovir therapy after a negative cytomegalovirus antigenemia test result in seropositive kidney transplant recipients. J Antimicrob Chemother 2013 Jan 16. [Epub ahead of print].
  13. Lee SO, Rim JH, Sung H, et al. Comparison of higher dose and lower dose ganciclovir for cytomegalovirus prophylaxis in seropositive heart transplant recipients. Transpl Infect Dis 2010;12:31-37. https://doi.org/10.1111/j.1399-3062.2009.00450.x
  14. Ki HK, Sohn KM, Rhee JY, et al. Usefulness of cytomegalovirus (CMV) antigenemia assay after liver transplantation. Infect Chemother 2005;37:199-207.
  15. Len O, Gavalda J, Aguado JM, et al. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients. Clin Infect Dis 2008;46:20-27. https://doi.org/10.1086/523590
  16. Jang EY, Park SY, Lee EJ, et al. Diagnostic performance of the cytomegalovirus (CMV) antigenemia assay in patients with CMV gastrointestinal disease. Clin Infect Dis 2009;48: e121-e124. https://doi.org/10.1086/599116
  17. Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2010;10:157-161. https://doi.org/10.1111/j.1600-6143.2009.02861.x
  18. Basse G, Mengelle C, Kamar N, et al. Disseminated herpes simplex type-2 (HSV-2) infection after solid-organ transplantation. Infection 2008;36:62-64. https://doi.org/10.1007/s15010-007-6366-7
  19. Yoon SA, Park SH, Yang CW, et al. Herpes simplex virus and varicella zoster virus infection in renal transplant recipients. J Korean Soc Transplant 1991;5:83-89.
  20. Koh GB, Kim T, Kim SH, et al. Increased incidence of herpes zoster in the setting of cytomegalovirus preemptive therapy after kidney transplantation. Transpl Infect Dis 2013 [In press].
  21. Allen U, Preiksaitis J; AST Infectious Diseases Community of Practice. Epstein-barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant 2009;9(Suppl 4):S87-S96. https://doi.org/10.1111/j.1600-6143.2009.02898.x
  22. Gardner SD, Field AM, Coleman DV, Hulme B. New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet 1971;1:1253-1257.
  23. Coleman DV, Mackenzie EF, Gardner SD, Poulding JM, Amer B, Russell WJ. Human polyomavirus (BK) infection and ureteric stenosis in renal allograft recipients. J Clin Pathol 1978;31:338-347. https://doi.org/10.1136/jcp.31.4.338
  24. Purighalla R, Shapiro R, McCauley J, Randhawa P. BK virus infection in a kidney allograft diagnosed by needle biopsy. Am J Kidney Dis 1995;26:671-673. https://doi.org/10.1016/0272-6386(95)90608-8
  25. Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002;347: 488-496. https://doi.org/10.1056/NEJMoa020439
  26. Chung BH, Hong YA, Kim HG, et al. Clinical usefulness of BK virus plasma quantitative PCR to prevent BK virus associated nephropathy. Transpl Int 2012;25:687-695. https://doi.org/10.1111/j.1432-2277.2012.01480.x
  27. Kim HC, Hwang EA, Han SY, Park SB, Park KK. Polyomavirus nephropathy after renal transplantation: a single centre experience. Nephrology (Carlton) 2005;10:198-203. https://doi.org/10.1111/j.1440-1797.2005.00393.x
  28. Lee KW, Lee HH, Lee DS, et al. Polymerase chain reaction for the diagnosis of human polyomavirus-associated nephropathy in renal transplant recipients. Transplant Proc 2004; 36:2116-2117. https://doi.org/10.1016/j.transproceed.2004.08.081
  29. Randhawa P, Brennan DC. BK virus infection in transplant recipients: an overview and update. Am J Transplant 2006; 6:2000-2005. https://doi.org/10.1111/j.1600-6143.2006.01403.x
  30. Sung H, Choi BH, Pyo YJ, Kim MN, Han DJ. Quantitation of BK virus DNA for diagnosis of BK virus-associated nephropathy in renal transplant recipients. J Korean Med Sci 2008;23:814-818. https://doi.org/10.3346/jkms.2008.23.5.814
  31. Eid AJ, Posfay-Barbe KM; AST Infectious Diseases Community of Practice. Parvovirus B19 in solid organ transplant recipients. Am J Transplant 2009;9(Suppl 4):S147-S150. https://doi.org/10.1111/j.1600-6143.2009.02905.x
  32. Park JB, Kim DJ, Woo SY, et al. Clinical implications of quantitative real time-polymerase chain reaction of parvovirus B19 in kidney transplant recipients-a prospective study. Transpl Int 2009;22:455-462. https://doi.org/10.1111/j.1432-2277.2008.00818.x
  33. McGrath D, Falagas ME, Freeman R, et al. Adenovirus infection in adult orthotopic liver transplant recipients: incidence and clinical significance. J Infect Dis 1998;177: 459-462. https://doi.org/10.1086/517375
  34. Michaels MG, Green M, Wald ER, Starzl TE. Adenovirus infection in pediatric liver transplant recipients. J Infect Dis 1992;165:170-174. https://doi.org/10.1093/infdis/165.1.170
  35. Ison MG, Michaels MG; AST Infectious Diseases Community of Practice. RNA respiratory viral infections in solid organ transplant recipients. Am J Transplant 2009; 9(Suppl 4):S166-S172. https://doi.org/10.1111/j.1600-6143.2009.02908.x
  36. Horn DL, Fishman JA, Steinbach WJ, et al. Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis 2007;59:407-414. https://doi.org/10.1016/j.diagmicrobio.2007.06.008
  37. Lee JS, Shin JH, Lee K, et al. Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea. Yonsei Med J 2007;48:779-786. https://doi.org/10.3349/ymj.2007.48.5.779
  38. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-535. https://doi.org/10.1086/596757
  39. Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001;7:375-381. https://doi.org/10.3201/eid0703.017302
  40. Singh N, Alexander BD, Lortholary O, et al. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin- inhibitor agents on mortality. J Infect Dis 2007; 195:756-764. https://doi.org/10.1086/511438
  41. Mueller NJ, Fishman JA. Asymptomatic pulmonary cryptococcosis in solid organ transplantation: report of four cases and review of the literature. Transpl Infect Dis 2003; 5:140-143. https://doi.org/10.1034/j.1399-3062.2003.00026.x
  42. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis 2010;50:291-322. https://doi.org/10.1086/649858
  43. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-1821. https://doi.org/10.1086/588660
  44. Park SY, Kim SH, Choi SH, et al. Clinical and radiological features of invasive pulmonary aspergillosis in transplant recipients and neutropenic patients. Transpl Infect Dis 2010;12:309-315. https://doi.org/10.1111/j.1399-3062.2010.00499.x
  45. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46: 327-360. https://doi.org/10.1086/525258
  46. Park WB, Kim NH, Kim KH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 2012;55:1080-1087. https://doi.org/10.1093/cid/cis599
  47. Lanternier F, Sun HY, Ribaud P, Singh N, Kontoyiannis DP, Lortholary O. Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis 2012;54:1629-1636.
  48. Kubak BM, Huprikar SS; AST Infectious Diseases Community of Practice. Emerging & rare fungal infections in solid organ transplant recipients. Am J Transplant 2009; 9(Suppl 4):S208-S226. https://doi.org/10.1111/j.1600-6143.2009.02913.x
  49. Martin SI, Fishman JA; AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant 2009;9(Suppl 4): S227-S233. https://doi.org/10.1111/j.1600-6143.2009.02914.x
  50. Pfaller MA, Anaissie EJ. Pneumocystis. In: Anaissie EJ, McGinnis MR, Pfaller MA, eds. Clinical Mycology. 2nd ed. Oxford: Churchill Livingstone, 2009:385-401.
  51. Smego RA Jr, Nagar S, Maloba B, Popara M. A metaanalysis of salvage therapy for Pneumocystis carinii pneumonia. Arch Intern Med 2001;161:1529-1533. https://doi.org/10.1001/archinte.161.12.1529
  52. Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome: the National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia. N Engl J Med 1990;323:1500-1504. https://doi.org/10.1056/NEJM199011223232131
  53. Moon SM, Kim T, Sung H, et al. Outcomes of moderateto- severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients. Antimicrob Agents Chemother 2011;55:4613-4618. https://doi.org/10.1128/AAC.00669-11
  54. Hong TW, Lee CH, Kim GH, Kang CM. Clinical characteristics of tuberculosis in kidney transplantation patients. J Korean Soc Transplant 2005;19:42-45.
  55. Jung H, Oh YM, Lee SD, et al. Clinical characteristics of tuberculosis in liver or heart transplant recipients. Tuberc Respir Dis 2006;61:440-446. https://doi.org/10.4046/trd.2006.61.5.440
  56. Ki HK, Son JS, Oh WS, et al. Infectious complications after liver transplantation according to donor: comparison between orthotopic and living donor transplantation. Infect Chemother 2004;36:139-147.
  57. Sung JY, Kim CW, Lee HH, et al. Clinical manifestations of mycobacterium tuberculosis infection after renal transplantation. J Korean Soc Transplant 2008;22:58-65.
  58. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662. https://doi.org/10.1164/rccm.167.4.603
  59. Subramanian A, Dorman S; AST Infectious Diseases Community of Practice. Mycobacterium tuberculosis in solid organ transplant recipients. Am J Transplant 2009; 9(Suppl 4):S57-S62. https://doi.org/10.1111/j.1600-6143.2009.02894.x
  60. Lopez-Montes A, Gallego E, Lopez E, et al. Treatment of tuberculosis with rifabutin in a renal transplant recipient. Am J Kidney Dis 2004;44:e59-e63. https://doi.org/10.1016/S0272-6386(04)00947-3
  61. Diagnosis and treatment of disease caused by nontuberculous mycobacteria: this official statement of the American Thoracic Society was approved by the Board of Directors, March 1997: Medical Section of the American Lung Association. Am J Respir Crit Care Med 1997;156(2 Pt 2):S1-S25. https://doi.org/10.1164/ajrccm.156.2.atsstatement
  62. Dorman S, Subramanian A; AST Infectious Diseases Community of Practice. Nontuberculous mycobacteria in solid organ transplant recipients. Am J Transplant 2009; 9(Suppl 4):S63-S69. https://doi.org/10.1111/j.1600-6143.2009.02895.x

피인용 문헌

  1. Risk factors in the progression of BK virus-associated nephropathy in renal transplant recipients vol.30, pp.6, 2013, https://doi.org/10.3904/kjim.2015.30.6.865
  2. Knowledge, Anxiety, and Compliance with Preventive Behavior of Middle East Respiratory Syndrome (MERS) in Liver Transplant Patients vol.31, pp.3, 2013, https://doi.org/10.4285/jkstn.2017.31.3.117